Increased Serum Titers of Autoantibodies Against Oxidized LDL Cholesterol in Young Healthy Adults: An Evidence of a Protective Effect of These Antibodies?

Hellenic Journal of Cardiology

Volumn 44, Issue 6, 2003, Pages 374-384

  Karabinos, Ilias K ^a,d   Koulouris, Spyridon ^a   Melpidou, Aggeliki ^b   Makris, Georgios ^a   Kranidis, Athanasios ^a   Papageorgakis, Nikolaos ^b   Moshovitis, Ilias ^a   Kalofoutis, Christos ^c   Zoulien, Zerar ^b   Exadaktylos, Nikolaos ^a   Kalofoutis, Anastasios ^c  

^a Cardiology Department   (Greece)

^b EVANGELISMOS HOSPITAL   (Greece)

^c UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^d NONE   (Greece)

Author keywords

Atherosclerosis; Autoantibodies; Oxidative stress; Oxidized LDL

Indexed keywords

APOLIPOPROTEIN A; APOLIPOPROTEIN B; AUTOANTIBODY; CHOLESTEROL; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; OXIDIZED LOW DENSITY LIPOPROTEIN; OXIDIZED LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGE; AGED; ANTIBODY PRODUCTION; ANTIBODY TITER; ARTICLE; BLOOD SAMPLING; CHOLESTEROL BLOOD LEVEL; CORONARY ARTERY ATHEROSCLEROSIS; CORRELATION ANALYSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; EXERCISE TEST; FEMALE; HUMAN; HUMAN EXPERIMENT; LINEAR REGRESSION ANALYSIS; LIPOPROTEIN BLOOD LEVEL; MALE; MULTIVARIATE ANALYSIS; NORMAL HUMAN; OXIDATION; PREDICTION; PROTECTION; TRANSTHORACIC ECHOCARDIOGRAPHY; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0842312309     PISSN: 10117970     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Singal PK, Petkau A, Gerrard JM, et al: Free radicals in health and disease. Mol Cell Biochem 1988; 84: 121-122.
2. Kako KJ: Free radical effects on membrane protein in myocardial inschemia/reperfusion injury. J Mol Cell Cardiol 1987; 19: 209-211.
3. Paradies G, Ruggiere FM, Petrosillo G, et al: Peroxidative damage to cardiac mitochondria: cytochrome oxidase and cardiolipin alterations. FEBS Lett 1998; 424: 155-158.
4. Virella G, Virella I, Leman RB, et al: Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers. Int J Clin Lab Res 1993; 23: 95-101.
5. Salonen JT. Yla-Herttuala S, Yamamoto R, et al: Autoantibody against oxidized LDL and progression of carotid atherosclerosis. Lancet 1992; 339: 883.
6. Maggi E, Finardi G, Poli M, et al: Specificity of autoantibodies against axidized LDL as an additional marker for atherosclerotic risk. Coronary Artery Disease 1993; 4: 1119-1125.
7. Bergmark C, Wu R, De Faire U, et al: Patients with early-onset peripheral vascular disease have increased levels of autoantibodies against oxidized LDL. Arterioscler Thromb Vasc Biol 1995; 15: 441-445.
8. Hulthe J, Bokemark L, Fagerberg B, et al: Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men. Arterioscler Thromb Vasc Biol 2001; 21: 101.
9. Iribarren C, Folsom AR, Jacobs DR, et al: Association of serum vitamin levels, LDL susceptibility to oxidation, and autoantibodies against MDA-LDL with carotid atherosclerosis. Arterioscler Thromb Vasc Biol 1997; 17: 1171.
10. Fukumoto M, Shoji T, Emoto M, et al: Antibodies against oxidized LDL and carotid artery intima-media thickness in a healthy population. Arterioscler Thromb Vasc Biol 2000; 20: 703-710.
11. Hulthe J, Wiklund O, Hurt-Camejio Eva, et al: Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules and phospholipase A2. Arterioscler Thromb Vasc Biol 2001; 21: 269.
12. Puurunen M, Manttari M, Manninen V, et al: Antibody against oxidized low-density lipoprotein predicting myocardial infarction. Arch Intern Med 1994; 154: 2603-2605.
13. Musfafa A, Nituyanand S, Berglund L, et al: Circulating immune complexes in 50-year-old men as a strong and independent risk factor for myocardial infarction. Circulation 2000; 102: 2576-2581.
14. Wu R, Nityanand S, Berglund L, et al: Antibodies against cardiolipin and oxidatively modified LDL in 50-year-old men predict myocardial infarction. Arterioscler Thromb Vasc Biol 1997; 17 (11): 3159-3163.
15. Ejaz A, Trifunovic J, Stegmayr B, et al: Autoantibodies against oxidatively modified LDL do not constitute a risk factor for stroke. Stroke 1999; 2541-2546.
16. Itabe H, Yamamoto H, Imanaka T, et al: Sensitive detection of oxidatively modified low density lipoprotein using a monoclonal antibody. J Lipid Res 1996; 37: 45-53.
17. Shoji T, Nishzawa Y, Fukumoto M, et al: Inverse relationship between circulating oxidized low density lipoprotein (oxLDL) and anti-oxLDL antibody levels inhealthy subjects. Atherosclerosis 2000; 148: 171-177.
18. Wiklund O, Witztum JL, Carew TE, et al: Turnover and tissue sites of degradation of glucosylated low density lipoprotein in normal and immunized rabbits. J Lipid Res 1987; 28: 1098-1109.
19. Horkko S, Bird DA, Miller E, et al: Monoclonal autoantibodies specific for oxidized low-density lipoproteins. J Clin Invest 1999; 103: 117-128.
20. Griffith RL, Virella, GT, Stevenson HC, et al: Low density lipoprotein metabolism by human macrophages activated with low density lipoprotein immune complexes: a possible mechanism of foam cell formation. J Exp Med 1988; 168: 1041-1059.
21. Khoo JC, Miller E, Pio F, et al: Monoclonal antibodies against LDL further enhance macrophage uptake of LDL aggregates. Arterioscler Thromb Vasc Biol 1992; 12: 1258-1266.
22. Ling WH, Lougheed M, Suzuki H, et al: Oxidized or acetylated low density lipoproteins are rapidly cleared by the liver in mice with disruption of the scavenger receptor class A type I/II gene. J Clin Invest 1997; 100: 244-252.
23. Hansson GK, Holm J, Holm S, et al: T lymphocytes inhibit the vascular response to injury. Proc Natl Acad Sci USA. 1991; 94: 2516-2520.
24. Rosellar SE, Schonfeld G, Daugherty A: Enhanced development of atherosclerosis in cholesterol-fed rabbids by suppression of cell-mediated immunity. J Clin Invest 1995; 96: 1389-1394.
25. Dansky HM, Charlton SA, Harper MM, et al: T and B lymphocytes play a minor role in atherosclerotic plaque formation in the apolipoprotein E-deficient mouse. Proc Natl Acad Sci 1997; 94: 4642-4646.
26. Hulthe J, Wikstrand J, Lidell A, et al: Antibody titers against oxidized LDL are not elevated in patients with familiar hypercholesterolemia. Arterioscler Thromb Vasc Biol 1998; 18: 1203-1211.
27. Uusitupa M, Niskanen L, Luoma J, et al: Autoantibodies against oxidized LDL do not predict atherosclerotic vascular disease in non-insulin-dependent diabetes mellitus. Arterioscler Thromb Vasc Biol 1996; 16: 1236.
28. Wu R, Lefvert AK: Autoantibodies against oxidized low density lipoproteins (oxLDL): characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL. Clin Exp Immunol 1995; 102: 174-180.
29. Libby P, Hansson GK: Biology of disease: involvement of the immune system in human atherogenesis: current knowledge and unanswered questions. Lab Invest 1991; 64: 5-15.
30. Zannis V, Kardasis D: The revolution of HDL. Atheroma 2002; 6: 1-2.
31. Navab M, Berliner J, Watson A, et al: The yin and yang of oxidation in the development of the fatty streak. Arterioscler Thromb Vasc Biol 1996; 16: 831-838.
32. Shah P, Kaul S, Nilsson J, et al: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part I. Circulation 2001; 104: 2376-2383.
33. Shah P, Kaul S, Nilsson J, et al: Exploiting the vascular protective effects of high-density lipoprotein and its apolipoproteins: an idea whose time for testing is coming, part II. Circulation 2001; 104: 2498-2502.
34. Navab M, Van Lenten B, Reddy S, et al: High-density lipoprotein and the dynamics of atherosclerotic lesions. Circulation 2001; 104: 2386-2387.
35. Tsimikas S, Palinski W, Witztum J, et al: Circulating autoantibodies to oxidized LDL correlate with arterial accumulation and depletion of oxidized LDL in LDL receptor-deficient mice. Arterioscler Thromb Vasc Biol 2001; 21: 95-101.
36. Van de Vijver L, Steyger R, Van Poppel G, et al: Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls. Atherosclerosis 1996; 122: 245-253.